You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


US approval for Boehringer Ingelheim, Lilly’s heart failure drug Jardiance

Jardiance (empagliflozin) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of cardiovascular death plus hospitalisation for adults with heart failure with reduced ejection fraction (HFrEF).